Skip to content
DataLookout
Menu

STEATO-FHNCT06634160

Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia

StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion date changed from estimate of Jan 30, 2027 to Oct 22, 2026
    • Study completion moved earlier from Jan 30, 2028 to Oct 22, 2027
    • Site details revised at 3 of 3 sites
  2. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Dec 1, 2026 to Jan 30, 2027
    • Study completion date: Dec 1, 2027 to Jan 30, 2028
    • Start date changed from estimate of Dec 1, 2024 to Jan 30, 2025
    • Site details revised at 3 of 3 sites
  3. Notable Eligibility criteria expanded, about 1 word
    • Site contacts updated at 1 of 3 sites
    v3
  4. Minor Secondary endpoints revised (7)
    • Site contacts updated at 1 of 3 sites
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Presence of steatosis in HeFH patients
Timeframe: 1 day

Secondary (7)

Establish the prevalence of hepatic fibrosis
Evaluate the prevalence of diabetes among HeFH patients, according to the presence or absence of steatosis or fibrosis
Evaluate the association between anthropometric measures (weight, height, waist circumference, and calculated BMI) and the presence of hepatic steatosis or fibrosis.
Evaluate the association between LDL-cholesterol and time of exposure to elevated LDL-cholesterol (Gallo et al. J Clin Lipidol 2017) with the prevalence of steatosis or fibrosis
Evaluate the proportion of patients with hepatic steatosis or fibrosis according to the nature of the genetic mutation
Show 2 moreShow less
Evaluate the link between the presence of hepatic steatosis or fibrosis and the risk of cardiovascular disease
Determine factors associated with the presence of steatosis or hepatic fibrosis

Arms and interventions

Study population

The study population must correspond to the research inclusion criteria. A fibroscan will be performed on each patient enrolled in the study. Each participant will also be offered a biological sample for an ancillary study.

Diagnostic tests: Fibroscan

Other: Sample collection

Sites

3 sites in 1 country